Literature DB >> 1376017

Analysis of four diverse population groups indicates that a subset of cystic fibrosis mutations occur in common among Caucasians.

G R Cutting1, S M Curristin, E Nash, B J Rosenstein, I Lerer, D Abeliovich, A Hill, C Graham.   

Abstract

To determine the nature and frequency of non-delta F508 cystic fibrosis (CF) mutations among diverse populations, we have sequenced exons 9-12 and 19-23 of the CF transmembrane conductance regulator (CFTR) gene from 128 CF chromosomes (39 U.S. Caucasian, 27 African-American, 42 Northern Irish, and 20 Israeli chromosomes). These regions were chosen because they encode the two putative ATP-binding folds of CFTR, domains which appear to have functional significance. In addition, CFTR exons 1 and 2 were analyzed in the American patients. Mutations were found on 49 of the 128 CF chromosomes. Nineteen different mutations were observed; six were novel, while the remaining 13 had been reported previously by our group or by other investigators. Six of nine different mutations found in African-American patients were unique to that population. However, the vast majority of the mutations found in U.S. Caucasians (eight of nine), Northern Irish (four of five), and Israelis (three of three) also occurred in other Caucasian groups. The preponderance of previously reported mutations in these three groups suggested that a subset of the non-delta F508 mutations occur in common among Caucasians. A survey of mutation frequencies in other Caucasian groups confirmed this observation. Unfortunately, this subset accounts for less than half of non-delta F508 CF mutations in most groups. These data suggest that screening for delta F508 and this select group of mutations will efficiently and economically maximize the number of CF mutations identified in Caucasian groups. However, it will be difficult to detect more than 90% of mutant CFTR alleles except in ethnically and geographically discrete populations where CF is the result of founder effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376017      PMCID: PMC1682572     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  46 in total

1.  The search for south European cystic fibrosis mutations: identification of two new mutations, four variants, and intronic sequences.

Authors:  P Gasparini; V Nunes; A Savoia; M Dognini; N Morral; A Gaona; A Bonizzato; M Chillon; F Sangiuolo; G Novelli
Journal:  Genomics       Date:  1991-05       Impact factor: 5.736

2.  Discrimination between recurrent mutation and identity by descent: application to point mutations in exon 11 of the cystic fibrosis (CFTR) gene.

Authors:  J Reiss; D N Cooper; J Bal; R Slomski; G R Cutting; M Krawczak
Journal:  Hum Genet       Date:  1991-08       Impact factor: 4.132

3.  The ethics of cystic fibrosis carrier screening: where do we stand?

Authors:  M De Braekeleer; M J Mélançon
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

4.  A mutation in the second nucleotide binding fold of the cystic fibrosis gene.

Authors:  L Osborne; R Knight; G Santis; M Hodson
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

5.  Is population screening for cystic fibrosis appropriate now?

Authors:  F Gilbert
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025

6.  Analysis of DNA polymorphism haplotypes linked to the cystic fibrosis locus in North American black and Caucasian families supports the existence of multiple mutations of the cystic fibrosis gene.

Authors:  G R Cutting; S E Antonarakis; K H Buetow; L M Kasch; B J Rosenstein; H H Kazazian
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

7.  Linkage of cystic fibrosis to two tightly linked DNA markers: joint report from a collaborative study.

Authors:  A Beaudet; A Bowcock; M Buchwald; L Cavalli-Sforza; M Farrall; M C King; K Klinger; J M Lalouel; G Lathrop; S Naylor
Journal:  Am J Hum Genet       Date:  1986-12       Impact factor: 11.025

8.  A 5' splice-region G----C mutation in exon 1 of the human beta-globin gene inhibits pre-mRNA splicing: a mechanism for beta+-thalassemia.

Authors:  M Vidaud; R Gattoni; J Stevenin; D Vidaud; S Amselem; J Chibani; J Rosa; M Goossens
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

9.  Sequence structures of a mouse major urinary protein gene and pseudogene compared.

Authors:  A J Clark; P Ghazal; R W Bingham; D Barrett; J O Bishop
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

10.  Molecular characterization of seven beta-thalassemia mutations in Asian Indians.

Authors:  H H Kazazian; S H Orkin; S E Antonarakis; J P Sexton; C D Boehm; S C Goff; P G Waber
Journal:  EMBO J       Date:  1984-03       Impact factor: 11.598

View more
  17 in total

1.  A transformed human epithelial cell line that retains tight junctions post crisis.

Authors:  A L Cozens; M J Yezzi; M Yamaya; D Steiger; J A Wagner; S S Garber; L Chin; E M Simon; G R Cutting; P Gardner
Journal:  In Vitro Cell Dev Biol       Date:  1992 Nov-Dec

2.  Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population.

Authors:  D Abeliovich; I P Lavon; I Lerer; T Cohen; C Springer; A Avital; G R Cutting
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

3.  Cystic fibrosis genotypes and views on screening are both heterogeneous and population related.

Authors:  C R Scriver; T M Fujiwara
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

4.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.

Authors:  P W Miller; A Hamosh; M Macek; P A Greenberger; J MacLean; S M Walden; R G Slavin; G R Cutting
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

5.  PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population.

Authors:  W W Grody; C Dunkel-Schetter; Z H Tatsugawa; M A Fox; C Y Fang; R M Cantor; J M Novak; H N Bass; B F Crandall
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

6.  Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population.

Authors:  J Zielenski; T M Fujiwara; D Markiewicz; A J Paradis; A I Anacleto; B Richards; R H Schwartz; K W Klinger; L C Tsui; K Morgan
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

Review 7.  Spectrum of mutations in cystic fibrosis.

Authors:  G R Cutting
Journal:  J Bioenerg Biomembr       Date:  1993-02       Impact factor: 2.945

8.  Anonymous marker loci within 400 kb of HLA-A generate haplotypes in linkage disequilibrium with the hemochromatosis gene (HFE)

Authors:  J Yaouanq; M Perichon; M Chorney; P Pontarotti; A Le Treut; A el Kahloun; V Mauvieux; M Blayau; A M Jouanolle; B Chauvel
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

9.  394delTT: a Nordic cystic fibrosis mutation.

Authors:  M Schwartz; M Anvret; M Claustres; H G Eiken; K Eiklid; C Schaedel; L Stolpe; L Tranebjaerg
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

10.  Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis mutations.

Authors:  T Dörk; R Fislage; T Neumann; B Wulf; B Tümmler
Journal:  Hum Genet       Date:  1994-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.